profit from every $100 of sales.
$0$100
Inspire Medical Systems
$61.10+0.93% today
-29.6% in 1 year
1-year low $40.051-year high $143.99
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
You pay $12.17 for every $1 of profit it makes in a year.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Inspire Medical Systems sold, what it kept, and what it did with the cash.
Sales went from $408 million in 2022 to $912 million in 2025, with $145 million of profit last year.
SalesProfit
Inspire Medical Systems handed back more cash to shareholders than it generated last year.
Buybacks $175M
Free cash flow 2025$78M
Bought back its own shares$175M
Paid as dividends–
Cash vs. debt$105M vs. $32M
Inspire Medical Systems vs. similar companies
Inspire Medical Systems grows the fastest of these 5 and is the cheapest for its profits.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Inspire Medical Systems | 12.2× · Cheap | ||
 Boston Scientific | 22.2× · Fair price | ||
 Koninklijke Philips | 30.1× · Expensive | ||
 Steris | 32.8× · Expensive | ||
 Zimmer Biomet Holdings | 27.7× · Fair price |
AI analysis
An AI analyst reads Inspire Medical Systems's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 408 | 625 | 803 | 912 | |
| 342 | 528 | 680 | 779 | |
| -48 | -40 | 36 | 51 | |
| -41 | -17 | 65 | 80 | |
| -45 | -21 | 54 | 145 | |
| -1.60 | -0.72 | 1.75 | 4.89 | |
| 83.8% | 84.5% | 84.7% | 85.4% | |
| -11.7% | -6.4% | 4.5% | 5.6% | |
| -11.0% | -3.4% | 6.7% | 15.9% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 565 | 677 | 808 | 907 |
| Cash | 442 | 186 | 150 | 105 |
| Total debt | 9 | 25 | 32 | 32 |
| Total liabilities | 69 | 104 | 119 | 126 |
| 496 | 573 | 690 | 781 | |
| 28 | 29 | 30 | 30 | |
| -6.7% | -2.6% | 6.4% | 6.4% | |
| -9.0% | -3.7% | 7.8% | 18.6% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 12 | 25 | 130 | 117 | |
| 9 | 24 | 39 | 38 | |
| 2 | 1 | 91 | 78 | |
| Dividends paid | – | – | – | – |
| 0 | 0 | 75 | 175 | |
| 52 | 82 | 116 | 130 |
Valuation
- 12.2×
- 32.8×
- –
- 1.5×
- 1.9×
- 22.6×
- 21.3×
- 4.4%
- 8.2%
- 0.0%
Profitability
- 85.4%
- 5.6%
- 15.9%
- 7.9%
- 6.2%
- -0.6%
- 18.0%
- 14.4%
- 6.2%
- 11.1%
Growth
- +30.8%
- –
- −13.9%
- –
- +1.9%
Financial health
- -1.0×
- 0.04
- 3.2%
- 374.6×
- 6.34
- 4.48
- 1.00
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 50%of 964
Bottom 35%of 898
Top 14%of 651
Top 17%of 911
Top 27%of 991
What analysts expect
- Average price target
- $91.33
- Range
- $56.00 – $180.00
- 13 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 4, 2026 | 0.10 | -0.28 | +136.3% |
| Feb 11, 2026 | 1.65 | 0.69 | +139.1% |
| Nov 3, 2025 | 0.38 | -0.15 | +353.3% |
| Aug 4, 2025 | 0.45 | 0.22 | +104.5% |
| May 5, 2025 | 0.10 | -0.23 | +143.5% |
| Feb 10, 2025 | 1.15 | 0.74 | +55.4% |
| Nov 4, 2024 | 0.60 | 0.08 | +650.0% |
| Aug 6, 2024 | 0.32 | -0.14 | +328.6% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
3/7Passes 3 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
58No pass
Benjamin Graham
72Pass
Philip Fisher
64Pass
Peter Lynch
97Pass
Joel Greenblatt
21No pass
Charlie Munger
48No pass
Terry Smith
42No pass
Questions about Inspire Medical Systems
Is Inspire Medical Systems a good stock to buy?
A solid business, and the price looks low. 3 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Inspire Medical Systems AI analysis
What does Inspire Medical Systems do?
Inspire Medical Systems, Inc., a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. It is in Medical - Devices.
Does Inspire Medical Systems pay a dividend?
No. Inspire Medical Systems does not pay a dividend at the moment; in 2025 it returned $175 million to shareholders by buying back its own shares.
Is Inspire Medical Systems stock halal?
Yes. Inspire Medical Systems passes our halal screen: its business is permitted and its debt is 2% of its market value, under the 30% limit. How we check
How has Inspire Medical Systems stock done over the past year?
Down 29.6% over the past twelve months, to $61.10. It traded between $40.05 and $143.99 and is 57.6% below its high.
Who are Inspire Medical Systems's competitors?
The largest listed companies in the same industry are Boston Scientific, Koninklijke Philips, Steris and Zimmer Biomet Holdings. The peers table on this page compares their profit, growth and price with Inspire Medical Systems's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.